Asset profile
PG-102
Peptide
Evidence outlook · lead readout
NCT06309667 · Healthy, Overweight
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06309667: Every dose cohort in this study randomized participants to PG-102 or matching placebo under double-blind conditions, a controlled design, but results have not been posted, so adverse-event rates cannot yet be compared between groups.
The source does not cite the trial's registry number and reports the sponsor's disclosure second-hand; identity rests on this being the sponsor's only phase 1 study enrolling obese participants.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.